

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Galvin, Katherine et al.**

Application No.: **10/067,741**

Group No.: **1632**

Filed: **February 8, 2002**

Examiner: **Peter Paras Jr.**

For: **COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS
OF CARDIOVASCULAR DISEASE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. Form PTO/SB/08B (substitute for Form PTO-1449) (1 page)
3. Copies of Listed Information Items Accompanying This Statement

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Diana Gentile

(type or print name of person certifying)

Date: March 9, 2004

Practitioner's Docket No. MPI95-001CP1CP1CN1M

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

March 9, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By


Jean M. Silveri
Reg. No. 39,030
40 Landsdowne Street
Cambridge, MA 02139
Telephone - (617) 679-7336
Facsimile - (617) 551-8820

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	1	of	1	Application Number	10/067,741
				Filing Date	February 8, 2002
				First Named Inventor	Galvin, Katherine et al.
				Group Art Unit	1632
				Examiner Name	Peter Paras Jr.
				Attorney Docket Number	MPI95-001CP1CP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		
	C1	Murray, J. D. et al., "Production of Transgenic Merino Sheep by Microinjection of Ovine Metallothionein-Ovine Growth Hormone Fusion Genes", Reprod. Fertil. Dev. 1:147-155 (1989)		
	C2	Powell, B. C. et al., "Transgenic Sheep and Wool Growth: Possibilities and Current Status", Reprod. Dev. 6:615-623 (1994)		
	C3	Clements J. E. et al., "Development of Transgenic Sheep that Express the Visna Virus Envelope Gene", Virology 200 :370-380 (1994)		
	C4	Janne, J. et al., "Transgenic Animals as Bioproducers of Therapeutic Proteins", Annals of Medicine 24:273-280 (1992)		
	C5	Ebert, K et al., "Transgenic Production of a Variant of Human Tissue-Type Plasminogen Activator in Goat Milk : Generation of Transgenic Goats and Analysis of Expression", Bio/Technology 9:835-838 (1991)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.